Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metronidazole, quantity: 7.5 mg/g - gel - excipient ingredients: carbomer 974p; propylene glycol; sodium hydroxide; disodium edetate; propyl hydroxybenzoate; methyl hydroxybenzoate; purified water - zidoval vaginal gel 0.75% is indicated in the treatment of symptomatic bacterial vaginosis (formerly referred to as haemophilus vaginalis vaginitis, gardnerella vaginalis vaginitis, non-specific vaginitis, corynebacterium vaginale vaginitis or anaerobic vaginosis). note: for purpose of this indicated, a clincial diagnosis of bacterial vaginosis is usually defined by the presence of at least three of the following four criteria: a) vaginal discharge ph of greater than 4.5, b) a vaginal discharge emitting a "fishy" amine odour when mixed with a 10% koh solution, c) a vaginal discharge containing clue cells on wet mount microscopy examination, d) a gram stain consistent with a diagnosis of bacterial vaginosis (lactobacillus morphotype absent of markedly decreased, gardnerella morphotype predominant flora, white blood cells absent or few, mobiluncus morphotype may or may not be present). a diagnosis of bacterial vaginosis requires that other pathogens which may be associated with genital infection, such as trichomonas vaginalis, candida albicans, chlamydia trachomatis and neisseria gonorrhoeae, should be ruled out be appropriate laboratory means.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 100 mg in 1 g - gelnique is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency [see clinical studies (14 )]. the use of gelnique is contraindicated in the following conditions: - urinary retention - gastric retention - uncontrolled narrow-angle glaucoma - known serious hypersensitivity reaction to gelnique, oxybutynin, or to any of the components of gelnique [see warnings and precautions (5.3 , 5.4) ]. pregnancy category b there are no adequate and well-controlled studies of topical or oral oxybutynin use in pregnant women. subcutaneous administration to rats at doses up to 25 mg/kg (approximately 50 times the human exposure based on surface area) and to rabbits at doses up to 0.4 mg/kg (approximately 1 times the human exposure) revealed no evidence of harm to the fetus due to oxybutynin chloride. the safety of gelnique administration to women who are or who may become pregnant has not been established. therefore, gelnique should not

Kenya - English - Pharmacy and Poisons Board

fdc limited 5774 00200 - ciprofloxacin eye/ear drops - eye drops - ciprofloxacin eye/ear drops 0.03%w/v - ophthalmological and otological preparation:

Ireland - English - HPRA (Health Products Regulatory Authority)

alissa healthcare research limited - dexamethasone sodium phosphate - eye drops, solution - 1.0 milligram(s)/millilitre - corticosteroids, plain; dexamethasone - corticosteroids, plain - for treatment of non-infectious inflammatory conditions affecting the anterior segment of the eye

Canada - English - Health Canada

allergan pharma co. - oxybutynin chloride - gel - 10% - oxybutynin chloride 10% - antimuscarinics

Australia - English - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - phenylephrine hydrochloride, quantity: 100 mg/ml - eye drops, solution - excipient ingredients: sodium metabisulfite; disodium edetate; purified water - phenylephrine is a directly acting sympathomimetic agent used topically in the eye as a mydriatic. minims phenylephrine hydrochloride eye drops are indicated to dilate the pupil for diagnostic or therapeutic procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - oxybuprocaine hydrochloride, quantity: 4 mg/ml - eye drops, solution - excipient ingredients: purified water; hydrochloric acid - to produce local anaesthesia in the eye.

Australia - English - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - tetracaine (amethocaine) hydrochloride, quantity: 10 mg/ml - eye drops, solution - excipient ingredients: purified water; hydrochloric acid - to produce local anaesthesia in the eye.

Australia - English - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - tetracaine (amethocaine) hydrochloride, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: purified water; hydrochloric acid - to produce local anaesthesia in the eye.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - tobramycin, quantity: 3 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; boric acid; benzalkonium chloride; sodium hydroxide; tyloxapol; hydrochloric acid; sodium sulfate; purified water - tobrex(tobramycin) eye drops are topical antibiotics indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobrex.